Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AC-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
Details : AC-101 is a novel RIPK2 inhibitor, small molecule drug candidate, which is being developed for the treatment of moderate-to-severe ulcerative colitis.
Product Name : AC-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2025
Lead Product(s) : AC-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diacerein
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-201 effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1.
Product Name : AC-201
Product Type : Microorganism
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : Diacerein
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
